MedicineEurope PMC
Ranked by formulaVerdict: NotableAdvancing morphological profiling with self-supervised learning through comparative insights into representation learning of cellular perturbations
Self-supervised learning (SSL) enables scalable, label-free foundation models (FMs) that learn task-agnostic representations directly from images, bypassing cell segmentation and feature engineering inherent to…
Key numbers
- 37% gains in site-averaged mean
VerdictWorth a reader's time today.
Abstract
Self-supervised learning (SSL) enables scalable, label-free foundation models (FMs) that learn task-agnostic representations directly from images, bypassing cell segmentation and feature engineering inherent to classical morphological profiling. We present a large-scale evaluation of SSL FMs for image-based phenotypic profiling, covering contrastive (DINO), masked-based generative (MAE, iTPN) and hybrid (DINOv2) learning mechanisms, pretrained on all unannotated chemical perturbations from the Joint Undertaking for Morphological Profiling-Cell Painting (JUMP-CP) dataset (119,876 compounds, ~1.77 million images, 7 laboratories). Here we show that top-performing SSL models outperformed CellProfiler in compound-replicate retrieval on the held-out JUMP-Target2 set (302 annotated compounds, P ≤ 0.001). DINO and DINOv2 generalized across diverse perturbations and cell types, outperforming CellProfiler with 31-37% gains in site-averaged mean average precision for mechanism-of-action retrieval on EU-OPENSCREEN Bioactives (2,464 compounds), and consistently surpassing masked-based models across all benchmarks. This study provides a systematic assessment of SSL approaches for advancing morphological profiling and offers pretrained FMs to accelerate drug discovery.
The editor's rubric
- Leverage4 / 5
- A general-purpose tool used across several fields (Adam, ResNet, LoRA, next-generation sequencing).
- Magnitude3 / 5
- Large gain: roughly 2x, or a clear new state of the art on a hard, unsaturated problem.
- Evidence4 / 5
- Strong: large scale, preregistered, independently replicated, or a well-powered randomized trial.
- Novelty3 / 5
- A genuinely new approach to an open problem.
- Trajectory3 / 5
- A clear path to scale.
- Stakes2 / 5
- Benefits a professional community (practitioners, clinicians, engineers).
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: method (we propose, we report); breadth (general-purpose, generalizes); gains (outperforms); novelty (discovery); verification (p-value, error bars, held-out test); scale (scalable); stakes (global scale).
How the score was computed
Desks place stronger verdicts first, then use this score to order work within the same verdict.
- Merit
- 6.3 / 10
- Adjusted merit
- 5.2 / 10
- Attention
- 0%
- Freshness
- 85%
- Citations0 (reference 20, via openalex, Oct 31, 2026, 05:48 UTC)